Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study

2009 ◽  
Vol 24 (5) ◽  
pp. 423-428 ◽  
Author(s):  
Brian P. Brennan ◽  
Kate V. Fogarty ◽  
Jacqueline L. Roberts ◽  
Karina A. Reynolds ◽  
Harrison G. Pope ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Pilot Study ◽  
Open Label ◽  
Irritable Bowel

scholarly journals Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevalence of Nickel Sensitivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 341 ◽  
Author(s):  
Raffaele Borghini ◽  
Maria Grazia Porpora ◽  
Rossella Casale ◽  
Mariacatia Marino ◽  
Emilia Palmieri ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Contact Dermatitis ◽  
Pilot Study ◽  
Gastrointestinal Disorders ◽  
Open Label ◽  
High Prevalence ◽  
Intestinal Symptoms ◽  
Irritable Bowel ◽  
Allergic Contact ◽  
Positive Results

Alimentary nickel (Ni) may result in allergic contact mucositis (ACM), whose prevalence is >30% and may present with IBS-like and extra-intestinal symptoms. These symptoms are also frequent in endometriosis, and Ni allergic contact dermatitis has already been observed in endometriosis. Therefore, intestinal and extra-intestinal symptoms in endometriosis may depend on a Ni ACM, and a low-Ni diet could improve symptoms. We studied the prevalence of Ni ACM in endometriosis and focused on the effects of a low-Ni diet on gastrointestinal, extra-intestinal, and gynecological symptoms. We recruited 84 women with endometriosis, symptomatic for gastrointestinal disorders. Thirty-one out of 84 patients completed the study. They underwent Ni oral mucosa patch test (omPT), questionnaire for intestinal/extra-intestinal/gynecological symptoms, and a low-Ni diet. Clinical evaluation was performed at baseline (T0) and after three months (T1). Twenty-eight out 31 (90.3%) patients showed Ni omPT positive results, with Ni ACM diagnosis, whereas three out of 31 (9.7%) patients showed negative Ni omPT. After three months of low-Ni diet, all gastrointestinal, extra-intestinal and gynecological symptoms showed a statistically significant reduction. Ni ACM has a high prevalence in endometriosis and a low-Ni diet may be recommended in this condition to reduce gastrointestinal, extra-intestinal and gynecological symptoms.

An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder

2016 ◽  
Vol 36 (6) ◽  
pp. 710-715 ◽  
Author(s):  
Roberto Lewis-Fernández ◽  
Peter Lam ◽  
Susan Lucak ◽  
Hanga Galfalvy ◽  
Elizabeth Jackson ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Major Depressive Disorder ◽  
Pilot Study ◽  
Depressive Disorder ◽  
Open Label ◽  
Major Depressive ◽  
Irritable Bowel

scholarly journals Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial

2012 ◽  
Vol 18 (3) ◽  
pp. 317-323 ◽  
Author(s):  
Yasushi Fukushima ◽  
Hidekazu Suzuki ◽  
Juntaro Matsuzaki ◽  
Arihiro Kiyosue ◽  
Toshifumi Hibi
Keyword(s):  
Irritable Bowel Syndrome ◽  
Pilot Trial ◽  
Open Label ◽  
Irritable Bowel

Transcutaneous auricular vagus nerve stimulation for the treatment of irritable bowel syndrome: a pilot, open-label study

2020 ◽  
Vol 3 (1) ◽  
pp. 5-12
Author(s):  
François Mion ◽  
Sonia Pellissier ◽  
Aurélien Garros ◽  
Henri Damon ◽  
Sabine Roman ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Vagus Nerve ◽  
Open Label ◽  
Open Label Study ◽  
Biological Variables ◽  
Randomized Controlled Studies ◽  
Transit Times ◽  
Blood Cytokines ◽  
Irritable Bowel ◽  
Left Vagus

Aim: Irritable bowel syndrome (IBS) is a frequent disease, associating chronic abdominal pain and abnormal bowel habits. The sympatho-vagal balance may be altered in IBS. We tested the effect of transcutaneous auricular stimulation of the left vagus nerve (taVNS) on symptoms and physiological and biological variables. Patients & methods: Twelve IBS women agreed to apply taVNS for 6 months. Evaluation was based on feasibility, symptoms, psychological questionnaires, fecal caprotectin, blood cytokines and bowel transit times. Results: Nine patients completed the trial: there was a significant improvement of symptoms at 3 and 6 months although none of the measured variables were modified by taVNS. Conclusion: The results suggest taVNS is feasible and may improve IBS symptoms. Randomized controlled studies are needed to confirm these preliminary results. ClinicalTrials.gov : NCT02420158.

Sign in / Sign up

Export Citation Format

Share Document